Wall Street analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post earnings of ($0.73) per share for the current quarter, according to Zacks. Three analysts have made estimates for Seres Therapeutics’ earnings, with estimates ranging from ($0.79) to ($0.68). Seres Therapeutics posted earnings per share of ($0.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 15.9%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 15th.
According to Zacks, analysts expect that Seres Therapeutics will report full year earnings of ($2.33) per share for the current year, with EPS estimates ranging from ($2.78) to ($2.18). For the next financial year, analysts expect that the firm will report earnings of ($2.67) per share, with EPS estimates ranging from ($2.97) to ($2.48). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Seres Therapeutics.
A number of research firms have recently issued reports on MCRB. BidaskClub cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 7th. Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Three analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Seres Therapeutics has an average rating of “Buy” and a consensus target price of $18.00.
Seres Therapeutics (MCRB) traded up $0.01 during mid-day trading on Friday, hitting $9.43. 87,200 shares of the stock were exchanged, compared to its average volume of 140,780. The company has a market cap of $381.79, a PE ratio of -4.45 and a beta of 0.24. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a one year low of $7.90 and a one year high of $17.42.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.